CytomX Therapeutics (NASDAQ:CTMX) Hits New 52-Week Low – What’s Next?

Posted by Geri Gentry on Oct 8th, 2026

CytomX Therapeutics, Inc. (NASDAQ:CTMX – Get Free Report) shares hit a new 52-week low on Thursday. The stock traded as low as $2.46 and last traded at $2.4550, with a volume of 152325 shares traded. The stock had previously closed at $2.55.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on CTMX shares. Zacks Research cut CytomX Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 19th. JPMorgan Chase & Co. dropped their target price on CytomX Therapeutics from $12.00 to $11.00 and set an “overweight” rating on the stock in a report on Thursday, August 13th. Weiss Ratings reiterated a “sell (d)” rating on shares of CytomX Therapeutics in a research report on Friday, September 11th. Wall Street Zen downgraded CytomX Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 23rd. Finally, Guggenheim decreased their price target on CytomX Therapeutics from $15.00 to $14.00 and set a “buy” rating for the company in a report on Monday, August 10th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, CytomX Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $11.90.

Read Our Latest Research Report on CytomX Therapeutics

CytomX Therapeutics Stock Down 4.1%

The company’s 50-day moving average is $3.17 and its 200 day moving average is $3.58. The company has a market cap of $532.77 million, a price-to-earnings ratio of -4.92 and a beta of 2.21.

CytomX Therapeutics (NASDAQ:CTMX – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01). CytomX Therapeutics had a negative return on equity of 38.46% and a negative net margin of 435.21%.The firm had revenue of $1.42 million during the quarter, compared to analyst estimates of $12.39 million. Analysts predict that CytomX Therapeutics, Inc. will post -0.4 EPS for the current fiscal year.

Hedge Funds Weigh In On CytomX Therapeutics

A number of large investors have recently bought and sold shares of the business. BlackRock Inc. purchased a new position in CytomX Therapeutics during the second quarter worth approximately $65,849,000. Bank of America Corp DE acquired a new stake in CytomX Therapeutics in the second quarter valued at approximately $56,560,000. Elmind Capital LP purchased a new stake in shares of CytomX Therapeutics in the second quarter valued at approximately $17,062,500. Siren L.L.C. purchased a new stake in shares of CytomX Therapeutics in the first quarter valued at approximately $16,251,000. Finally, ADAR1 Capital Management LLC acquired a new position in shares of CytomX Therapeutics during the 2nd quarter worth approximately $12,619,000. Institutional investors and hedge funds own 67.77% of the company’s stock.

CytomX Therapeutics Company Profile

(Get Free Report)

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based medicines for cancer and other serious diseases. The company’s technology is designed to keep therapeutic antibodies inactive in healthy tissue and activate them in disease sites, particularly within the tumor microenvironment, with the goal of improving treatment precision and reducing systemic toxicity.

CytomX’s Probody Therapeutics platform uses conditionally activated antibodies and related molecules.